Screening For BCRL In Targeted Therapy For Breast Cancer

ConditionsLymphedema Lymphedema Arm Lymphedema of Upper Arm Lymphedema of Upper Limb Lymphedema of the Hands Edema Edema Arm Breast Cancer Lymphedema Breast Cancer Metastatic Breast Cancer Stage Breast Cancer

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexFemale

Age18-80

SponsorMassachusetts General Hospital

About this trial

This a prospective, longitudinal study designed to track edema and Breast Cancer Related Lymphedema (BCRL) onset in breast cancer patients taking targeted therapy treatments for early and metastatic breast cancer.

A Perometer and Sozo devise will be used to measure volume changes

Eligibility criteria

Qualifiers

Subjects who are receiving treatment in the MGH Breast Cancer Center who are enrolled in a DF/HCC-regulated targeted therapy trial for the treatment of early or metastatic breast cancer or patients being treated with a targeted therapy that may alter their risk of developing edema or BCRL will be eligible.

Females between 18 and 80 years of age

With a history of breast cancer

4 weeks or more post-surgery

Disqualifiers

None

Trial design

Treatments tested in this trial

Perometer
SOZO device

Treatment groups

261 Participants

are divided into 2 treatment groups

Sponsors and collaborators

Massachusetts General Hospital

Lead sponsor

Heinz Family Foundation

Collaborator

Source ClinicalTrials.gov